Please assess the completion status of the following clinical trial:

Trial Title: Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD)~* patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient~* child or adolescent patients must be 10 to 16 years old~* must be able to communicate in English~* must be able to swallow capsules~* be reliable to keep appointments for clinic visits and all related tests~Exclusion Criteria:~* patients who weigh less than 25 Kg or greater than 70 Kg~* patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months~* patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder~* females who are pregnant or breastfeeding~* patients with a history of severe allergy to more than one class of medications~* patients with documented history of bipolar I or bipolar II disorder, or psychosis

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.

Based on this trial design, predict the completion outcome and termination type (if applicable).